Pfizer Inc Stock Piotroski F Score
| PFE Stock | USD 25.39 0.03 0.12% |
Pfizer | Piotroski F Score |
At this time, it appears that Pfizer's Piotroski F Score is Healthy. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
5.0
Piotroski F Score - Healthy
| Current Return On Assets | Positive |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Positive |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | Decrease |
| Current Ratio Change | Increase |
| Long Term Debt Over Assets Change | Higher Leverage |
| Change In Outstending Shares | Increase |
| Change in Gross Margin | Increase |
Pfizer Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Pfizer is to make sure Pfizer is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Pfizer's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Pfizer's financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Return On Assets | 0.0089 | 0.0094 |
|
| |||||
| Asset Turnover | 0.25 | 0.2583 |
|
| |||||
| Gross Profit Margin | 0.62 | 0.5006 |
|
| |||||
| Net Debt | 75.8 B | 72.2 B |
|
| |||||
| Total Current Liabilities | 50.2 B | 47.8 B |
|
| |||||
| Non Current Liabilities Total | 93.9 B | 89.4 B |
|
| |||||
| Total Assets | 237.8 B | 226.5 B |
|
| |||||
| Total Current Assets | 32.2 B | 43.3 B |
|
| |||||
| Total Cash From Operating Activities | 12.4 B | 8.7 B |
|
|
Pfizer Inc F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Pfizer's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Pfizer in a much-optimized way.
Click cells to compare fundamentals
About Pfizer Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Common Stock Shares Outstanding |
|
Pfizer ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pfizer's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pfizer's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
About Pfizer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Pfizer Altman Z Score, Pfizer Correlation, Pfizer Valuation, as well as analyze Pfizer Alpha and Beta and Pfizer Hype Analysis. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.